文献速递肝病

NLRP3在急性和慢性胆汁淤积性肝损伤中的双向作用

Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury.
PubMed 文献 · Hepatology · 2021-03-26

该研究分析了胆汁淤积性肝损伤患者及胆管结扎小鼠模型中NLRP3的作用。慢性胆汁淤积时NLRP3激活与疾病活动相关;急性期NLRP3缺失加重炎症和肝损伤,而慢性期NLRP3缺失减轻肝损伤、炎症和纤维化,MCC950可减轻野生型小鼠疾病进展。

要点

  • 慢性胆汁淤积患者和小鼠中NLRP3激活与疾病活动相关。
  • 急性胆管结扎时NLRP3缺失加重炎症和肝损伤,伴更强凋亡和坏死性凋亡。
  • 慢性胆汁淤积时NLRP3缺失减轻肝损伤、炎症和桥接纤维化。

核心结论

  • NLRP3激活与原发性胆汁性胆管炎患者的疾病活动相关。
  • NLRP3在急性和慢性胆汁淤积性肝损伤中作用不同,与肾损伤中的作用相反。
  • 慢性胆汁淤积的疾病进展可通过小分子靶向,提示对人类有潜在临床获益,可减轻肝和肾损伤。

研究设计与样本

  • 分析胆汁淤积性肝损伤患者的NLRP3激活。
  • 野生型和Nlrp3-/-小鼠接受胆管结扎2天或28天。
  • 在野生型小鼠中给予NLRP3小分子抑制剂MCC950。

主要发现

  • 急性和慢性胆管结扎后Nlrp3缺失小鼠肾损伤和纤维化减轻。
  • 急性胆管结扎时Nlrp3缺失小鼠炎症和肝损伤增加,伴更强凋亡和坏死性凋亡。
  • 慢性胆汁淤积时NLRP3缺失导致肝损伤和炎症减轻。
  • 胆管结扎28天后野生型小鼠出现桥接纤维化,而NLRP3敲除小鼠无桥接纤维化。
  • MCC950减轻野生型小鼠胆管结扎诱导的疾病进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cholestatic liver injury leads to cell death and subsequent inflammation and fibrosis. As shown for primary biliary cholangitis (PBC), the mechanisms and circuits between different cell death pathways leading to disease progression are incompletely defined. Common bile duct ligation (BDL) is a well-established murine model to mimic cholestatic liver injury. Here, we hypothesized that pyroptotic cell death by the Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3 (Nlrp3) inflammasome plays an essential role during human and murine cholestasis. APPROACH AND RESULTS: NLRP3 activation was analyzed in humans with cholestatic liver injury. Wild-type (WT) and Nlrp3-/- mice were subjected to BDL for 2 or 28 days. Chronic cholestasis in humans and mice is associated with NLRP3 activation and correlates with disease activity. Acute BDL in Nlrp3-deficient mice triggered increased inflammation as well as liver injury, associated with stronger apoptotic and necroptotic cell death. In contrast, NLRP3 deletion led to decreased liver injury and inflammation in chronic cholestasis. Moreover, bridging fibrosis was observed in WT, but not in NLRP3 knockout, mice 28 days after BDL. In contrast, lack of NLRP3 expression attenuated kidney injury and fibrosis after acute and chronic BDL. Importantly, administration of MCC950, an NLRP3 small molecule inhibitor, reduced BDL-induced disease progression in WT mice. CONCLUSIONS: NLRP3 activation correlates with disease activity in patients with PBC. NLRP3 has a differential role during acute and chronic cholestatic liver injury in contrast to kidney injury. Disease progression during chronic cholestasis can be targeted through small molecules and thus suggests a potential clinical benefit for humans, attenuating liver and kidney injury.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Frissen M, Liao L, Schneider KM, et al. Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury. Hepatology. 2021. PMID: 32748971. doi:10.1002/hep.31494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。